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ABSTRACT. Alfacalcidol (1-alpha-hydroxyvitamin D3) is
a non-endogenous analog of vitamin D which can bypass
the renal and intestinal regulatory mechanisms that
control the production of calcitriol (1,25-hydroxyvitamin
D3, the active form of vitamin D, D-Hormone). Alfa-
calcidol may be metabolized into calcitriol with a limit-
ed risk of hypercalcemia. Alfacalcidol and calcitriol
have been evaluated in animal and human studies as-
sessing their effects on bone mineral density and fracture
rates. More recently, they have been shown to produce
beneficial effects in muscle, immune system, and auto-
immune diseases, including rheumatoid arthritis. This pa-
per discusses the therapeutic efficacy of alfacalcidol in
reports in which it has been proposed as an interesting
alternative to vitamin D or calcitriol. Some recent find-
ings about general metabolism and regulation of vitamin
D and its analogs are discussed. The biological and
clinical effects of alfacalcidol in post-menopausal os-
teoporosis are reviewed, followed by critical appraisal of
its efficacy in preventing bone loss and falls in the el-
derly. The last two sections discuss the role of D-analogs
in regulating the immune system, with particular regard
to rheumatoid arthritis. The main results of this re-
view show that alfacalcidol may have a wider range of
therapeutic applicability, beyond simply restricting it to
patients in hemodialysis or peritoneal dialysis with high
serum levels of intact PTH.
(Aging Clin Exp Res 2005; 17: 133-142)
©2005, Editrice Kurtis
INTRODUCTION
Until 1980, no-one imagined that vitamin D and its
metabolites 25(OH)D, 24,25(OH)2D and 1,25(OH)2D,
well-known for their central roles in calcium and bone
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metabolism, might play an important role in regulating
the immune system. Recent advances in our under-
standing of their mechanism of action opened up new
research fields, due not only to their unique interaction
with bone cells but also to their modulation of the im-
mune system. Although alfacalcidol, 1-α(OH)D3, a syn-
thetic D-Hormone analog, has been studied for several
decades, its extensive mechanism of action is still not ful-
ly elucidated. The aim of this paper was to review the
available evidence of the biological and clinical effects of
alfacalcidol in post-menopausal osteoporosis (PMOP) and
rheumatoid arthritis (RA).
GENERAL METABOLISM OF VITAMIN D AND
ITS ANALOGS (FIGS. 1-2)
Vitamins D2 (ergocalciferol) and D3 (cholecalciferol)
are produced by the skin or absorbed from the gut.
They are metabolized into their active form, calcitriol,
by two successive steps: 25-hydroxylation in the liver to
25(OH)D, followed by 1α-hydroxylation in the renal
proximal tubules to 1,25-(OH)2D, yielding the biologi-
cally active form of vitamin D, calcitriol (1). Some oth-
er cells exhibit 1α-hydroxylase activity, including os-
teoblasts, placental cells, keratinocytes, macrophages
and some tumor cells. The role of the extrarenal pro-
duction of 1,25(OH)2D is still debated but, in normal
conditions, it does not significantly contribute to the cir-
culating levels of the hormone (2, 3). 24-hydroxylation,
producing 24,25-dihydroxyvitamin D [24,25(OH)2D] or
1,24,25-trihydroxyvitamin D, occurs in a wide range of
normal tissues and is believed to be important both to
catabolise vitamin D metabolites and to regulate the ac-
tive forms of vitamin D (4). 24,25(OH)2D is not in
fact inactive. Recent animal studies have shown that this
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metabolite can stimulate chondrocyte maturation (5), in-
crease bone mineral density in vitamin D-replete rats,
rabbits and dogs (6), and play a beneficial role in frac-
ture repair in chicks (7). 24,25(OH)2D has also been
shown to be a potent inhibitor of PTH secretion in hu-
mans (8). The interactions among calcitriol, alfacalcidol
and 24,25(OH)2D are still under study. Recent findings
in animal models suggest that both metabolites must be
present for optimal changes in bone metabolism (Fig.
2). The major enzymes involved in vitamin D hydrox-
ylation are mitochondrial mixed-function oxidases con-
taining cytochrome P450 with ferredoxin and heme-
binding domains (9). Until today, four cytochrome P450
molecular species (CYP27A1, CYP2C11, CYP2D25,
CYP3A4) have been identified as vitamin D3 25-hy-
droxylases (10, 11). Alfacalcidol (1-α(OH)D3) is a syn-
thetic derivate of vitamin D. Important for its metabo-
lization is the fact that hepatic 25-hydroxylation is un-
regulated and exclusively substrate-dependent. Con-
versely, the renal 1α-hydroxylase enzyme is stringent-
ly regulated by: the PTH cAMP-mediated pathway,
calcitonin in a different region of the proximal tubule,
and by 1,25(OH)2D itself, through negative feedback
regulation via its receptor (VDR) (2, 4). Thus, in situa-
tions in which the general vitamin D pathways are
disturbed, exogenous alfacalcidol may bypass these
regulatory systems to produce bioavailable calcitriol. Cir-
culating vitamin D metabolites measured in clinical
practice are 25(OH)D and 1,25(OH)2D (calcitriol). As
25(OH)D synthesis is substrate-, i.e., vitamin D-de-
pendent, serum levels of this metabolite are taken as a
measure of vitamin D status. Besides its classical actions
in calcium metabolism, it is now suggested that the hor-
monal form of vitamin D has many “uncommon” func-
tions, which have only been revealed as a result of
the identification and characterization of its receptor.
The VDR complex was discovered in 1975 (12). Many
tissues express VDR, including osteoblasts, intestinal,
muscle, distal renal, liver, parathyroid, and T-cells and
monocytes (13, 14). Calcitriol functions as a steroid hor-
mone which binds to a cytosolic VDR, resulting in se-
lective demasking of the genome of the nucleus (Fig. 3).
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Figure 1 - General vitamin D pathways.


















Figure 2 - Regulation of vitamin D metabolism.
OHase: OH-hydroxylase.
Two subtypes of VDR have recently been discovered us-
ing knock-out mice models. 1α,25(OH)2D(3)-depen-
dent regulation of DNA synthesis in chondrocytes re-
quires the presence of the 1,25-nVDR, although other
physiological responses to the vitamin D metabolite,
such as proteoglycan sulfating, involve regulation via the
1,25-mVDR(5). Because of the wide variety of tissues
in which VDR has been identified, the exploitation of vi-
tamin D compounds in treating various diseases has
been expanded. 
VITAMIN D DEFICIENCY: 
A HETEROGENEOUS CONDITION
“Vitamin D deficiency” collectively describes a number
of pathological conditions which include primary vita-
min D deficiency, calcitriol deficiency, and resistance to cal-
citriol. Primary vitamin D deficiency is due to inadequate
dietary intake or exposure to sunlight, and is not simply a
biochemical abnormality. It is regularly associated with sec-
ondary hyperparathyroidism, increased bone turnover,
bone loss, osteoporosis, and increased risk of fracture (15).
Vitamin D deficiency impairs the intestinal absorption
of calcium. PTH maintains normal serum calcium levels for
a time, despite decreased calcium absorption, by in-
creasing bone resorption; however, vitamin D deficiency
progressively causes resistance to the osteoclastic effects
of PTH on bone and a decrease in calcium renal tubular
reabsorption (16). PTH increases serum calcium but also
stimulates phosphaturia, resulting in hypophosphatemia
(16). These combined effects lead to a reduced bone
mineralization. Unlike primary vitamin D deficiency, pri-
mary calcitriol deficiency is not due to the limitation of pre-
cursors but to a defect in the synthesis of calcitriol, re-
ducing intestinal Ca absorption and increasing PTH and
bone resorption. The pathogenesis of primary calcitriol de-
ficiency is related to impaired ability of the kidney to
synthesize adequate amounts of calcitriol. It is common in
patients with renal insufficiency or failure. Resistance to cal-
citriol is related to aging-associated decline in the functions
of various tissues and organs, leading to reduced calcitri-
ol biological action despite its normal serum levels (17).
The potential cause of this resistance may be due to age-
related or unknown defects in regulation in the number or
a decrease in the affinity of VDR, which mediate ge-
nomic actions of vitamin D (18, 19). 
BIOLOGICAL EFFECTS OF ALFACALCIDOL
IN POST-MENOPAUSAL OSTEOPOROSIS
Alfacalcidol is a synthetic precursor of calcitriol, and is
converted into 1,25(OH)2D3, predominantly in the liver,
by 25-hydroxylation. 25-hydroxylation has been report-
ed to be catalyzed by both mitochondrial CYP27A and a
microsomal CYP2D25 vitamin D3 25-hydroxylase in the
liver (20, 21). Northern blotting and reverse transcription-
polymerase chain reaction experiments have revealed
that porcine CYP2D25 mRNA (showing 77% identity
with that of humans) is expressed at the highest level in
the liver and in small amounts in other tissues, including
muscle (20) and bone. As noted above, alfacalcidol by-
passes endogenous regulation by renal 1-α hydroxylase
and its pharmacokinetic profile is therefore very different
from that of calcitriol: after oral ingestion of calcitriol, peak
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Figure 3 - Vitamin D Receptor: structure and function.
DBP: vitamin D binding protein; VDRE: vitamin D responsive elements (specific DNA sequences); CaBP: calcium-binding protein; 24-OHase:
24-OH-hydroxylase; Alk Pase: Alkaline phosphatase; c-myc, c-fos, c-sis: protooncogen regulating cell proliferation and differentiation; RXR:
Retinoid X Receptor
serum 1,25(OH)2D3 is reached within 2 hours, whereas
oral ingestion of alfacalcidol causes a slow rise in serum
calcitriol with peak values after 8-18 hours. Calcitriol, up-
on absorption, acts immediately and directly on the VDR
in the intestinal mucosal cells to promote Ca absorp-
tion, leading to a rapid increase in serum calcium. In
contrast, alfacalcidol has very limited intestinal action, since
25-hydroxylase required for its metabolization into calcitriol
acts predominantly in the liver. Compared with calcitriol,
alfacalcidol allows for more progressive and longer pro-
duction of calcitriol together with a lower risk of hyper-
calcemia. This allows the lack of calcium absorption due
to VDR deficiency to be counterbalanced. 
It has been suggested (22) that pharmacological or
suprapharmacological doses of 1,25(OH)2D(3) stimulate
bone resorption by inducing RANKL, the ligand from
pre-osteoblastic cells binding to RANK on pre-osteoclastic
cells to promote the differentiation of osteoclasts (23).
Conversely, a certain range of physiological doses of vi-
tamin D inhibit PTH-induced bone resorption, the latter
mechanism appearing to be mediated, at least partly, by
suppression of PTH/PTHrP receptor-mediated signaling.
This may highlight the central role played by
1,25(OH)2D3 in bone formation and resorption cou-
pling. Indeed, the most important endocrine regulator of
PTH is calcitriol (24), which regulates PTH through its re-
ceptor by suppressing both the expression of the pre-
proparathyroid gene and parathyroid cell proliferation
(25). Alfacalcidol, by enhancing D-analog levels, indirectly
suppresses secondary hyperparathyroidism, which is
common in osteoporotic and elderly patients. The mech-
anism includes inhibition of the proliferation of parathy-
roid cells by reducing their apoptosis (26, 27) as well as
PTH synthesis and release (28), and of the effects of
PTH on bone (29, 30). Reduction of alkaline phos-
phatase activity has also been shown (31). Vitamin D
metabolites calcitriol and 24,25(OH)2D modulate the re-
sponse of bone and cartilage cells to 17 beta-estradiol
and dihydrotestosterone in both cell cultures and in vivo
rat models (32). They both reduce, by one order of
magnitude, the amount of sex steroids needed to stim-
ulate cultured osteoblast-like cells or rat embryo epi-
physeal cartilage cells, and synergistically increase the
maximal response of these cells (32). Notwithstanding
this, it has been shown that interactions among D-
analogs, VDR and oestrogen receptor (ER) are largely de-
pendent on gender groups, suggesting complex ER-
VDR-sex, ER-age-sex and VDR-age-sex interactions
may exist (33). The current data do not support the
strong role of 24,25(OH)2D alone in the regulation of os-
teoblast action and mineralization (34). Conversely, al-
facalcidol induces an increase in calcitonin secretion
(35) and normalization of uncoupled bone turnover
through an increase in transforming growth factor beta
(TGF-beta), which stimulates osteoblastic maturation,
and osteoprotegerin, which inhibits osteoclastic matu-
ration by inhibiting the RANKL-RANK system (36).
Calcitriol, by inhibiting bone-resorbing cytokines, specif-
ically TNF-alpha or osteoblastic apoptosis, induces a
modification in osteoclastic apoptosis, and an impact on
the remodeling process has been observed (37). Cor-
rection of the helper/suppressor ratio in patients with
high bone loss due to an increase in CD8 also appears
to be involved (38). 
CLINICAL EFFECTS OF ALFACALCIDOL
IN POST-MENOPAUSAL OSTEOPOROSIS
Several studies have investigated the clinical effects of
D-analogs (mainly calcitriol, alfacalcidol and 24,25(OH)2D)
on bone mineral density, fractures and bone metabolism
markers in PMOP. 24,25(OH)2D is still a poorly studied
compound, which has not shown any beneficial effects on
BMD and calcium metabolism in clinical studies (34).
We previously performed two meta-analyses review-
ing the clinical effects of D-analogs calcitriol and alfa-
calcidol (39), and compared their efficacies against that
of native vitamin D (40). Our first systematic review in-
cluded all randomized controled trials on alfacalcidol or
calcitriol versus calcium or placebo. Eight studies of al-
facalcidol (41-48) and a similar number of studies of
calcitriol (49-56) specifically focused on their respec-
tive clinical efficacies on bone loss and/or fracture.
Among trials of alfacalcidol, four (41-44) investigated
post-menopausal osteoporosis in women aged 60 and
more. Meta-analysis of these studies revealed the highly
significant effect of alfacalcidol on global and particularly
on spinal BMD, at a median duration of 18 months. Re-
garding non-spinal BMD, the data were too sparse for a
proper meta-analysis. Regarding fracture prevention,
we found a highly significant reduction (-47%) in the rel-
ative risk of lumbar spine fractures in the alfacalcidol
arms, compared with placebo or calcium alone, at a
median follow-up of 12 months. We were not able to find
relevant data on hip fracture prevention by alphacalcidol
in PMOP. However, we did find a trend toward in-
creased efficacy of alfacalcidol, compared with calcitriol,
in preventing decrease with BMD, and more specifical-
ly spinal BMD. In addition, studies on alfacalcidol, pooled
together, provided remarkably homogenous results
(pheterogeneity=0.66); studies on calcitriol did not (phetero-
geneity=0.01). These results suggested not only that alfa-
calcidol and calcitriol have similar efficacies, but also
that alfacalcidol may exert its BMD-preserving capabili-
ties in a wider range of clinical patterns.
Our second quantitative review (40) assessed the rel-
ative efficacies of D-analogs alfacalcidol and calcitriol
against their parent compound, vitamin D. Regarding
BMD, D-analogs exerted a significantly higher efficacy on
BMD at any site compared with native vitamin D, at a me-
dian duration of 24 months. When restricted to the lum-
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bar spine, this intertreatment difference remained signif-
icant whereas there were no significant differences re-
garding their efficacies on other measurement sites, in-
cluding hip. When comparing the adjusted global relative
risks for spinal and non-spinal fracture, alfacalcidol and cal-
citriol appeared to be significantly more effective ap-
proaches compared with vitamin D. Analysis of the dif-
ference between spinal and non-spinal fracture rates
confirmed the benefits of D-analogs, with significantly low-
er spinal and non-spinal fracture rates for D-analogs, on
the basis of 30 to 36 months follow-up. Despite the
lack of head-to-head trials in this field and the need for
more careful follow-up of calcemia, alfacalcidol may be
considered as an interesting alternative to native vita-
min D in preventing bone loss and fractures in PMOP.
ALFACALCIDOL AND MUSCULAR
FUNCTION
Muscle function, together with bone mineral density, is
an important determinant of fracture risk, especially in the
elderly (57). It was assumed for a century that vitamin D
deficiency was linked to disturbed muscle metabolism
(58). Vitamin D deficiency can impair intracellular Ca
metabolism in muscle cells. The Ca-depleted content of
mitochondria isolated from vitamin D-depleted chicks
has been shown to be low (59), and Ca uptake into the
sarcoplasmic reticulum is reduced during vitamin D defi-
ciency (60, 61). Animal studies have shown that the
actinomyosin content of myofibrils is reduced during ex-
perimental rickets (62). 
Several studies in humans have demonstrated the re-
lationship between D-hormone analogs and muscle func-
tion (63-65). Patients with osteomalacia suffer from
muscle weakness and have low serum levels of muscle en-
zymes (66). A recent study on chick embryonic muscle
cells provided direct evidence for the participation of
the VDR in non-genomic 1,25(OH)2D3 signal transduc-
tion. Activation of tyrosine phosphorylation cascades
through this mechanism may contribute to hormone
regulation of muscle growth (67). The results of a
prospective, population-based study showed that lower
25-OHD and higher PTH levels increase the risk of sar-
copenia in older men and women (68). A recent study has
shown that congestive heart failure is associated with low
vitamin D status (69). 
Several trials have provided evidence for the involve-
ment of D-analogs in preserving muscle function. Sup-
plementation with 357 or 1250 µg vitamin D or 50 µg
25(OH)D for 1 or 2 months normalized muscle strength
in patients with myopathy (66, 70). Leg extension pow-
er was positively correlated with serum 25(OH)D levels in
elderly males and with serum 1,25(OH)2D3 in the whole
group of males and females (64). Grady et al. (71) and
Lips et al. (72) did not show statistical improvement in
muscle function using calcitriol or vitamin D.  Glerup et al.
(73), Pfeifer et al. (74), and Bischof et al. (75) showed a
significant decrease in body sway and number of falls, cor-
responding to an improvement in muscle function using
native vitamin D. 
More recently, research has focused on alfacalcidol.
Dukas et al. (76) demonstrated that, in calcium-replete pa-
tients, alfacalcidol treatment significantly and safely reduced
the number of fallers in an elderly community-dwelling pop-
ulation (OR 0.45, 95% CI 0.21-0.97, p=0.042). Sato et
al. (44) reported a highly significant differential efficacy of
alfacalcidol on BMD depending on body side, in hemiplegic
patients. BMD on the intact side increased by 3.5%, but
decreased by 2.4% on the hemiplegic side over 6 months.
Some local factors, such as paralysis and immobilization,
may diminish the effect of alfacalcidol on bone formation
on the hemiplegic side. This is an argument favoring the
involvement of muscle 25-hydroxylase, which converts al-
facalcidol into active calcitriol on a local basis. Janssen et
al. (77) assessed the effects of alfacalcidol in vitamin D-de-
ficient elderly people. Muscle strength improved, as well as
walking distance and functional ability, which resulted in a
reduction in the number of falls and fractures. Additional
research is needed to clarify further to what extent alfa-
calcidol supplementation can preserve muscle strength
and prevent falls and fractures in elderly people.
IMMUNOLOGICAL ROLE
OF ALFACALCIDOL (FIG. 4)
In recent years, there has been an effort to understand
the possible non-calcemic roles played by vitamin D, in-
cluding its role in the immune system and, in particular, on
T-cell-mediated immunity. Vitamin D receptor is in fact
found in significant concentrations in T-lymphocytes and
macrophage populations (78, 79), but its highest con-
centration is found in immature immune cells of the thy-
mus and mature CD-8 T lymphocytes (80). Calcitriol
has recently aroused great interest as an immune modu-
lator with immunosuppressive activity, because of its
Alfacalcidol in PMOP and RA
Aging Clin Exp Res, Vol. 17, No. 2   137










Figure 4 - Interactions between calcitriol and the immune system.
Pietschmann et al. Bedeutung von Vitamin D im Immunsystem.
Journal Für Mineralstoffwechsel 2003; 10: 13-15. Reproduced by
kind permission of Krause & Pachernegg GMBH.
ability to shift T-cell responses from Th1 to Th2. The hor-
mone inhibits the production of lymphokines (IL-2, IFN-
gamma) and monocyte-derived cytokine (IL-12), leading
to inhibition of helper T-cell subset type 1 (Th1) (81, 82).
The significant role of vitamin D compounds as selective
immunosuppressants is illustrated by their ability to pre-
vent or even suppress animal models of autoimmune
disease. Several studies on animal models have shown that
1,25-dihydroxyvitamin has a significant impact on the de-
velopment of encephalomyelitis (83), rheumatoid arthri-
tis (84), systemic lupus erythematosus (85), type I diabetes
(86), and inflammatory bowel disease (87). Possible
mechanisms of suppression of these autoimmune disor-
ders by calcitriol have been presented. Notably, calcitriol
stimulates transforming growth factor TGFß-1 (88) and in-
terleukin production which, in turn, may suppress in-
flammatory T-cell activity. In support of this, calcitriol was
unable to suppress a murine model of human multiple
sclerosis in IL-4-deficient mice (80). It was shown to sup-
press proliferation of promyelocytes and promote their dif-
ferentiation into monocytes (89). Peripheral lympho-
cytes contain variable amounts of VDR. CD-8 lympho-
cytes have the highest concentrations, whereas CD-4
and macrophages have lower ones (90). 
The intrinsic effects of alfacalcidol, i.e., not those from
its metabolite calcitriol, on various immunological pa-
rameters including lymphocyte subsets are still not  clear-
ly demonstrated. However, interestingly, Yamauchi et
al. (91) showed that, in patients with rheumatoid arthritis,
the CD-4/CD-8 ratio remains stable in patients whose ini-
tial value was normal, whereas it decreases after alfacalcidol
treatment in patients whose initial values were abnor-
mally high. It has been demonstrated that the delayed hy-
persensitivity response to dinitrobenzene is impaired in vi-
tamin D deficient mice (92), which tends to confirm the
modulator control of 1,25-(OH)2D3 in T cell-mediated
immunity. The T-cell immune response depending on
D hormone levels displays a characteristic inverted “U”
curve (93). While this field requires more research in-
vestment, this particular activity of D-hormone analogs is
the rationale for studies and trials on alfacalcidol and cal-
citriol for treating autoimmune disorders, including RA.
ALFACALCIDOL IN RHEUMATOID
ARTHRITIS
Patients with RA are at high risk of developing both
generalized and periarticular osteoporosis (94) and are
thus at even higher risk of fractures (95). Local and sys-
temic osteoporosis are linked to increased production of
inflammatory cytokines (TNF alpha, IL-1 beta, IL-6), re-
sulting in increased formation and activation of osteo-
clasts (96-100). TNF-alpha may also interfere with
bone formation by promoting apoptosis of osteoblasts
(101). Bone loss appears very early and is correlated di-
rectly with disease activity (102). Later in the process, it
is associated with the negative effects of limited mobil-
ity, which may be related to decreased muscle function
in the elderly. Goertz et al. (103) and Lee et al. (104)
showed that VDR polymorphisms do not play a major
role in RA predisposition, but Gough et al. (105) did ob-
tain inverse results in female patients with early RA. In
parallel, predisposition towards osteoporosis has been
shown in certain VDR genotypes (106). High disease ac-
tivity in patients with RA has been associated with al-
terations in vitamin D metabolism and increased bone re-
sorption (84). The decrease in 1,25(OH)2D3 levels in
these patients may lead to a negative calcium balance
and inhibition of bone formation. Furthermore, low
levels of 1,25(OH)2D3 may raise levels of activated T-
cells and proliferation of lymphokine-activated killer
cells, thus accelerating the arthritic process (107). 
Whether glucocorticoids work positively or nega-
tively on generalized/periarticular osteoporosis in RA is
still controversial (108-110). The pathogenesis of cor-
ticosteroid-induced osteoporosis is complex. As a patho-
genetic co-factor, corticosteroids reduce intestinal calcium
absorption and increase renal calcium excretion, re-
sulting in compensatory increased PTH release and in-
creased sensitivity of bone to PTH. In addition, corti-
costeroids inhibit osteoblastic function (111) as well as
the favorable effects of growth factors and sex hor-
mones on bone (112, 113). Thus, bone loss in RA is
centered around primary inhibition of osteoblastic ac-
tivity, compounded by the effects of secondary hyper-
parathyroidism (114). It has recently been suggested that
the expression of D-hormone receptors (VDR) may be
decreased by corticosteroids, and that they probably
reduce the number of functional VDR (115, 116). This
may be an explanation for the efficacy of D-analogs in
treating PMOP. Corticosteroids inhibit IL-12 production
in human monocytes and enhance their capacity to in-
duce IL-4 synthesis in CD4+ lymphocytes (117). 
D-analogs have been shown to inhibit cytokines IL-1,
IL-6, TNF-alpha and particularly IL-12 (118). At the
cellular level, D-hormone may directly or indirectly reduce
the expression of Th1 helper cells by inhibition of IL-12
from monocytes (119). Therapy with alfacalcidol or cal-
citriol results in increased production of Th2 helper
cells, which produce bone-protective cytokines like IL-4
and IL-10 (120). D-analogs have been shown to have a
protective effect on osteoblasts against TNF-alpha-induced
cell death (101). 
Five intervention trials aimed at quantifying the effect
of vitamin D and its metabolites on the clinical expres-
sion of RA have been published. Andjelkovic et al.
(121) (alfacalcidol 2 µg/day/3 months), Brohult et al.
(122) (vitamin D 2500 µg/day/1-2 years) and Dottori et
al. (123) (25(OH)D 50 µg/day/1 month) have shown re-
ductions in disease activity or pain symptoms, whereas
Yamauchi et al. (124) (alfacalcidol 2 µg/day/4 months)
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and Hein et al. (125) (alfacalcidol 1 µg/day/2 months)
have not. With respect to these contradictory findings,
the exact role of alfacalcidol in the management of RA
remains unclear.
Various clinical studies have investigated the efficacy
of alfacalcidol in corticosteroid-induced bone loss, re-
gardless of the underlying disease. The main results of its
use in RA have been to preserve bone mass, not to in-
crease it (126). Gukasian et al. (127) reported an anal-
ysis of the anti-osteoporotic efficacy of alfacalcidol in 50
patients with RA. 30 RA patients received alfacalcidol
(0.75-1.0 µg/day) for 12 months and 20 control RA pa-
tients received a placebo. Alfacalcidol stabilized bone
mineral density at the femoral neck and lumbar spine. A
significant BMD increase was observed in those areas of
the proximal femur where cortical bone tissue prevails.
In a double-blind, placebo-controlled comparative trial of
16 weeks by Yamauchi et al. (91), 1.0-2.0 µg/day al-
facalcidol revealed 10% more patients with improvement
compared with the placebo group, but the difference be-
tween them did not reach significance. The OKT-
4/OKT-8 ratio was found not to change in patients
whose initial value was normal, whereas it decreased af-
ter alfacalcidol treatment in patients whose initial values
were higher. Bone mineral density was conserved in the
alfacalcidol group. Among all trials, taking efficacy on
bone loss into consideration, a dose of 1.0 µg/day was
judged to be suitable for safe, long-term treatment with
regard to the limited risk of hypercalcemia.
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